Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial (IND) application of its oral, highly active, and selective small molecule KRAS G12D inhibitor, ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The clinical trial application for ABSK141 has been approved by the NMPA [1] - ABSK141 is designed to target advanced solid tumors with the KRAS G12D mutation [1] - The drug is characterized as an oral, highly active, and highly selective small molecule inhibitor [1]

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial application (IND) of its oral, highly active, and selective small molecule KRAS G12D inhibitor, ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The clinical trial application for ABSK141 has been approved by NMPA [1] - ABSK141 is designed for patients with advanced solid tumors that have the KRAS G12D mutation [1] - The drug is characterized as an oral, highly active, and highly selective small molecule inhibitor [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) in China for its new drug clinical trial application for the oral, highly active, and selective small molecule KRAS G12D inhibitor ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The subsidiary involved is Shanghai Heyu Biopharmaceutical Technology Co., Ltd. [1] - The drug ABSK141 targets a specific mutation (KRAS G12D) associated with advanced solid tumors [1] - The approval marks a significant step in the development of targeted therapies for cancer treatment [1]

Core Viewpoint - The company He Yu-B (02256.HK) has received approval from the National Medical Products Administration (NMPA) in China for its clinical trial application of the oral, highly active, and selective small molecule KRAS G12D inhibitor ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The drug ABSK141 is specifically designed for patients with advanced solid tumors that have the KRAS G12D mutation [1] - The approval from NMPA marks a significant milestone for the company in advancing its oncology pipeline [1]